A compound called IC7Fc is doing something researchers didn't expect: it's working on two separate problems at once. In mice, it reduced the fatty buildup that clogs arteries and tamped down the inflammation that damages blood vessels over time. For a disease landscape where heart disease remains the world's leading killer, a treatment that addresses multiple risk factors simultaneously could reshape how doctors approach prevention.
The research, led by Professor Mark Febbraio at Monash Institute of Pharmaceutical Sciences, builds on earlier work showing IC7Fc could help manage type 2 diabetes. The new findings suggest it also slows atherosclerosis—the gradual accumulation of fatty deposits that restrict blood flow to the heart. "Even with common treatments that lower blood pressure and cholesterol, many people are still at risk," Febbraio said. "This shows there's more work to do."
What makes IC7Fc interesting is how it works differently depending on the body it's in. In earlier studies using obese mice, the compound reduced appetite and body fat. But in this latest round of experiments using lean mice prone to high cholesterol, IC7Fc didn't change weight or food intake at all—yet still protected the heart.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThis split behavior actually matters. It suggests the drug's weight-loss effects may be specific to obesity, while its heart-protective benefits—reducing cholesterol buildup and calming arterial inflammation—could help a broader population. A treatment that works through multiple pathways, not just one mechanism, is harder for disease to outmaneuver.
Febbraio frames it plainly: "IC7Fc could offer a dual benefit—helping reduce obesity in some, while protecting the heart in others." The next step is human trials. Mice don't always translate to people, and the dose, timing, and side effects all remain open questions. But the fact that a single compound is showing promise against two of the conditions most likely to shorten a life is worth watching closely.
